Literature DB >> 23568718

Adaptive immune responses in CNS autoimmune disease: mechanisms and therapeutic opportunities.

Rhoanne C McPherson1, Stephen M Anderton.   

Abstract

The processes underlying autoimmune CNS inflammation are complex, but key roles for autoimmune lymphocytes seem inevitable, based on clinical investigations in multiple sclerosis (MS) and related diseases such as neuromyelitis optica, together with the known pathogenic activity of T cells in experimental autoimmune encephalomyelitis (EAE) models. Despite intense investigation, the details of etiopathology in these diseases have been elusive. Here we describe recent advances in the rodent models that begin to allow a map of pathogenic and protective immunity to be drawn. This map might illuminate previous successful and unsuccessful therapeutic strategies targeting particular pathways, whilst also providing better opportunities for the future, leading to tailored intervention based on understanding the quality of each individual's autoimmune response.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23568718     DOI: 10.1007/s11481-013-9453-9

Source DB:  PubMed          Journal:  J Neuroimmune Pharmacol        ISSN: 1557-1890            Impact factor:   4.147


  225 in total

Review 1.  Tight junctions of the blood-brain barrier: development, composition and regulation.

Authors:  Hartwig Wolburg; Andrea Lippoldt
Journal:  Vascul Pharmacol       Date:  2002-06       Impact factor: 5.773

Review 2.  Lack of evidence for use of glatiramer acetate in multiple sclerosis.

Authors:  Luca M Munari; Graziella Filippini
Journal:  Lancet Neurol       Date:  2004-11       Impact factor: 44.182

3.  ICAM-1, VCAM-1, and MAdCAM-1 are expressed on choroid plexus epithelium but not endothelium and mediate binding of lymphocytes in vitro.

Authors:  B J Steffen; G Breier; E C Butcher; M Schulz; B Engelhardt
Journal:  Am J Pathol       Date:  1996-06       Impact factor: 4.307

4.  TGF-beta-induced myelin peptide-specific regulatory T cells mediate antigen-specific suppression of induction of experimental autoimmune encephalomyelitis.

Authors:  Hong Zhang; Joseph R Podojil; Judy Chang; Xunrong Luo; Stephen D Miller
Journal:  J Immunol       Date:  2010-05-07       Impact factor: 5.422

5.  Sphingosine 1-phosphate receptor agonists attenuate relapsing-remitting experimental autoimmune encephalitis in SJL mice.

Authors:  Michael Webb; Chui-Se Tham; Fen-Fen Lin; Karen Lariosa-Willingham; Naichen Yu; Jeffrey Hale; Suzanne Mandala; Jerold Chun; Tadimeti S Rao
Journal:  J Neuroimmunol       Date:  2004-08       Impact factor: 3.478

6.  Exacerbations of multiple sclerosis in patients treated with gamma interferon.

Authors:  H S Panitch; R L Hirsch; A S Haley; K P Johnson
Journal:  Lancet       Date:  1987-04-18       Impact factor: 79.321

7.  Multiple sclerosis. Distribution of T cells, T cell subsets and Ia-positive macrophages in lesions of different ages.

Authors:  U Traugott; E L Reinherz; C S Raine
Journal:  J Neuroimmunol       Date:  1983-06       Impact factor: 3.478

8.  Reversal of experimental allergic encephalomyelitis with monoclonal antibody to a T-cell subset marker.

Authors:  M K Waldor; S Sriram; R Hardy; L A Herzenberg; L A Herzenberg; L Lanier; M Lim; L Steinman
Journal:  Science       Date:  1985-01-25       Impact factor: 47.728

9.  Cytotoxic NKG2C+ CD4 T cells target oligodendrocytes in multiple sclerosis.

Authors:  Fatma Zaguia; Philippe Saikali; Samuel Ludwin; Jia Newcombe; Diane Beauseigle; Ellie McCrea; Pierre Duquette; Alexandre Prat; Jack P Antel; Nathalie Arbour
Journal:  J Immunol       Date:  2013-02-08       Impact factor: 5.422

10.  IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H).

Authors:  Joanne L Jones; Chia-Ling Phuah; Amanda L Cox; Sara A Thompson; Maria Ban; Jacqueline Shawcross; Amie Walton; Stephen J Sawcer; Alastair Compston; Alasdair J Coles
Journal:  J Clin Invest       Date:  2009-06-22       Impact factor: 14.808

View more
  6 in total

1.  Celastrol Ameliorates EAE Induction by Suppressing Pathogenic T Cell Responses in the Peripheral and Central Nervous Systems.

Authors:  Ying Wang; Lu Cao; Li-Min Xu; Fan-Fan Cao; Bin Peng; Xue Zhang; Yu-Fan Shen; Georges Uzan; Deng-Hai Zhang
Journal:  J Neuroimmune Pharmacol       Date:  2015-03-15       Impact factor: 4.147

2.  ESC-derived thymic epithelial cells expressing MOG prevents EAE by central and peripheral tolerance mechanisms.

Authors:  Min Su; Yujun Lin; Cheng Cui; Xiaohong Tian; Xiuling Lu; Zhixu He; Laijun Lai
Journal:  Cell Immunol       Date:  2017-10-18       Impact factor: 4.868

Review 3.  High-throughput sequencing of immune repertoires in multiple sclerosis.

Authors:  Andreas Lossius; Jorunn N Johansen; Frode Vartdal; Trygve Holmøy
Journal:  Ann Clin Transl Neurol       Date:  2016-02-25       Impact factor: 4.511

Review 4.  Expanding Role of T Cells in Human Autoimmune Diseases of the Central Nervous System.

Authors:  Deepti Pilli; Alicia Zou; Fiona Tea; Russell C Dale; Fabienne Brilot
Journal:  Front Immunol       Date:  2017-06-07       Impact factor: 7.561

Review 5.  Immune Response in Neurological Pathology: Emerging Role of Central and Peripheral Immune Crosstalk.

Authors:  Austin P Passaro; Abraham L Lebos; Yao Yao; Steven L Stice
Journal:  Front Immunol       Date:  2021-06-10       Impact factor: 7.561

6.  Exposure to inflammatory cytokines selectively limits GM-CSF production by induced T regulatory cells.

Authors:  Ben C Reynolds; Darryl G Turner; Rhoanne C McPherson; Catriona T Prendergast; Richard G Phelps; Neil A Turner; Richard A O'Connor; Stephen M Anderton
Journal:  Eur J Immunol       Date:  2014-10-01       Impact factor: 5.532

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.